BDO has provided buy side due diligence (alongside commercial diligence) to Kester Capital on the acquisition of Optibrium.
Kester Capital invests in Optibrium, a drug discovery software provider to the pharmaceutical and biotech industries.
The business’ customer base includes five of the top ten global pharmaceutical companies.
Optibrium is based in Cambridge and has offices in the USA in Boston and San Francisco. Its StarDrop™ product is a complete platform of integrated software for small molecule design, optimisation and data analysis that enhances the speed and productivity of the drug discovery process.